Evoke Pharma (EVOK) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Evoke Pharma Reports First Quarter 2016 Results
May 11, 2016 4:05 PM EDTSOLANA BEACH, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2016.
Dave Gonyer, R.Ph., President and CEO, stated, The start of 2016 has been a very significant time for Evoke as we are now one step closer to the potential commercialization of EVK-001 with the completion of enrollment in our pivotal Phase 3 trial. We look forward to providing study results early in the third quarter of this... More
